DarioHealth narrows loss as digital platform pivots to high-margin recurrent revenue

DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.

While the figure was down from $6.8 million in the prior-year period, management noted the decrease was primarily due to $1.3 million in non-recurring pharmaceutical revenue that did not repeat.

The company is intentionally moving away from one-time contracts in favor of its annual recurring B2B2C model.

Operational discipline was a highlight of the quarter.

Total operating expenses fell 21% year-over-year to $10.5 million, driven by leaner research and development and marketing spend.

This helped the company reduce its GAAP operating loss to $7.3 million, a 22% improvement from Q1 2025.

The net loss for the period stood at $8.2 million, or $0.23 per share.

DarioHealth’s "one-to-many" distribution strategy appears to be gaining momentum.

The company’s current channel partnerships, including blue-chip names like Solera and Amwell, provide access to 116 million covered lives.

Management revealed it is in the final contracting phase with a new partner—a major Northeastern hospital network—that could push its total reach above 175 million lives.

Elsewhere, the company added 10 new accounts during the quarter and reported a robust commercial pipeline valued at $127 million across 241 active opportunities.

As of March 31, 2026, DarioHealth held $20 million in cash and short-term deposits, which it believes is sufficient to support its trajectory toward cash flow breakeven, targeted for mid-2027.